FGFR3-related chondrodysplasia
MONDO:001968533 clinical trials for this condition and its sub-types, 0 tagged with FGFR3-related chondrodysplasia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of FGFR3-related chondrodysplasia
-
Achondroplasia 26 trials
-
Hypochondroplasia 9 trials
-
Thanatophoric dysplasia 0 trials
4 sub-types
- Kozlowski Warren Fisher syndrome 0 trials
- Thanatophoric dysplasia type 1 0 trials
- Thanatophoric dysplasia type 2 0 trials Sub-types →
- Thanatophoric dysplasia, Glasgow variant 0 trials
Most studied deeper sub-types
-
New pill could help kids with dwarfism grow – but early days
Disease control Recruiting nowThis study tests a daily oral drug called TYRA-300 in 92 children aged 3–10 with achondroplasia (a common form of dwarfism). The goal is to see if it safely increases their growth rate. Researchers will try different doses to find the best one. It's a Phase 2 trial, so it's still…
Phase 2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug aims to boost height in kids with dwarfism
Disease control Recruiting nowThis study tests a new medicine called BMN 333 against an existing drug (vosoritide) to see if it can safely improve growth in children with achondroplasia, the most common form of dwarfism. About 160 children aged 2 to 17 will take part. The goal is to measure how much they grow…
Phase 2/3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New pill could help kids with dwarfism grow better
Disease control Recruiting nowThis study tests an oral drug called infigratinib in infants and children under 3 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth and body proportions. The trial has several phases to find the right dose and then co…
Phase 2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Weekly shot may boost growth in teens with dwarfism
Disease control Recruiting nowThis study tests a weekly injection called navepegritide in 24 teenagers (ages 12-18) with achondroplasia, the most common form of dwarfism. The goal is to see if it safely increases growth rate over one year compared to a placebo. The treatment aims to manage the condition by im…
Phase 2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New weekly shot could boost growth in babies with dwarfism
Disease control Recruiting nowThis study tests a weekly injection called TransCon CNP in infants under 2 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth over 52 weeks. About 72 babies will take part, with some receiving the drug and others a pla…
Phase 2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for babies with rare dwarfism: daily shot may boost growth
Disease control Recruiting nowThis study tests a daily injection called vosoritide in infants and toddlers (0 to 3 years old) with hypochondroplasia, a genetic condition that causes short stature. The goal is to see if the drug safely improves growth over 52 weeks. About 60 children will receive either vosori…
Phase 2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New study tracks growth in kids with rare bone disorder
Knowledge-focused Recruiting nowThis study watches children aged 2.5 to 17 with hypochondroplasia, a condition causing short stature, to track their growth and health over time. No treatments or drugs are given. The goal is to learn more about how the condition affects growth, body proportions, thinking skills,…
Sponsor: QED Therapeutics, a BridgeBio company • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New study uses virtual tools to track achondroplasia over time
Knowledge-focused Recruiting nowThis study observes about 170 children and adults with achondroplasia in the United States over roughly 5 years. Researchers will collect health records and questionnaires to track growth, medical issues, surgeries, and quality of life. The goal is to better understand the condit…
Sponsor: BioMarin Pharmaceutical • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New registry aims to unlock secrets of bone disorder
Knowledge-focused Recruiting nowThis study is creating a database of health information from people with achondroplasia, a common form of dwarfism. Researchers will collect growth measurements and surgery records from up to 1,500 patients across several U.S. hospitals. The goal is to answer future questions abo…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Massive database aims to unlock secrets of facial birth defects
Knowledge-focused Recruiting nowThis study is creating a large database of genetic and physical information from 3100 children with craniofacial abnormalities, such as craniosynostosis and Pierre Robin sequence. Researchers will analyze this data to understand why these conditions vary so much from person to pe…
Sponsor: Imagine Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Wearable tech tracks movement in rare bone disorders
Knowledge-focused Recruiting nowThis study is for people aged 3 and older with achondroplasia or hypochondroplasia (types of skeletal dysplasia). It uses a wearable device called Syde® to measure limb movements over a year. The goal is to find out which movement measurements are reliable and useful for future r…
Sponsor: SYSNAV • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
New study tracks natural history of achondroplasia in kids
Knowledge-focused Recruiting nowThis study follows 260 children with achondroplasia (ages 2.5 to 11) for up to 2 years to collect data on growth, medical complications, and quality of life. No treatment is given—it is purely observational to better understand the condition's natural course.
Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC